Daiwa Securities Group Inc. Takes $1.95 Million Position in Puma Biotechnology Inc (PBYI)

Daiwa Securities Group Inc. purchased a new stake in shares of Puma Biotechnology Inc (NASDAQ:PBYI) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 19,744 shares of the biopharmaceutical company’s stock, valued at approximately $1,952,000. Daiwa Securities Group Inc. owned about 0.05% of Puma Biotechnology as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PBYI. New York State Common Retirement Fund boosted its holdings in Puma Biotechnology by 4.7% in the second quarter. New York State Common Retirement Fund now owns 32,247 shares of the biopharmaceutical company’s stock worth $2,818,000 after purchasing an additional 1,446 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in Puma Biotechnology by 26.0% in the third quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock worth $110,627,000 after purchasing an additional 190,500 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Puma Biotechnology by 9.6% in the third quarter. Schwab Charles Investment Management Inc. now owns 135,167 shares of the biopharmaceutical company’s stock worth $16,187,000 after purchasing an additional 11,787 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Puma Biotechnology by 265.6% in the third quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock worth $57,743,000 after purchasing an additional 350,300 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Puma Biotechnology by 17.9% in the third quarter. American Century Companies Inc. now owns 51,984 shares of the biopharmaceutical company’s stock worth $6,225,000 after purchasing an additional 7,882 shares during the last quarter. Hedge funds and other institutional investors own 96.21% of the company’s stock.

Puma Biotechnology Inc (NASDAQ PBYI) opened at $68.40 on Thursday. Puma Biotechnology Inc has a 52-week low of $28.35 and a 52-week high of $136.90. The firm has a market cap of $2,570.00, a P/E ratio of -8.35 and a beta of 0.18.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Alan H. Auerbach sold 10,692 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $991,683.00. Following the completion of the transaction, the insider now owns 4,155,931 shares in the company, valued at $385,462,600.25. The disclosure for this sale can be found here. Insiders sold 13,874 shares of company stock worth $1,303,616 over the last quarter. Insiders own 21.10% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, January 26th. BidaskClub cut shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Friday, January 26th. Bank of America dropped their target price on shares of Puma Biotechnology from $135.00 to $115.00 and set a “buy” rating on the stock in a report on Wednesday, January 24th. Citigroup dropped their target price on shares of Puma Biotechnology from $164.00 to $146.00 and set a “buy” rating on the stock in a report on Wednesday, January 24th. Finally, Credit Suisse Group dropped their target price on shares of Puma Biotechnology from $147.00 to $106.00 and set an “outperform” rating on the stock in a report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. Puma Biotechnology presently has an average rating of “Buy” and a consensus price target of $110.56.

ILLEGAL ACTIVITY NOTICE: “Daiwa Securities Group Inc. Takes $1.95 Million Position in Puma Biotechnology Inc (PBYI)” was reported by Week Herald and is owned by of Week Herald. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://weekherald.com/2018/02/15/daiwa-securities-group-inc-takes-1-95-million-position-in-puma-biotechnology-inc-pbyi.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply